Search results
Antoni Ribas is a Spanish American physician–scientist. He is a Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA) and Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center.
Antoni Ribas, MD, PhD, is professor of medicine, surgery, and molecular and medical pharmacology at the University of California Los Angeles (UCLA), director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA.
- (59)
- (310) 794-4955
- 100 Medical Plaza, Los Angeles, 90095
Dec 11, 2019 · View in: PubMed Mentions: 22 Fields: Com Computational Biology. Translation: Humans Cells. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib.
- Professor, Medicine
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26),...
Antoni Ribas, M.D., Ph.D., conducts laboratory and clinical research focused on malignant melanoma, an aggressive form of skin cancer for which few effective therapies exist. He seeks to develop immunotherapy and targeted stem cell-based approaches that harness a patient’s own immune system to combat melanoma and other cancers. For over two ...
Dr. Antoni Ribas is a world-renowned expert in cancer immunotherapy and a scientific advisor for Vial, a leading oncology CRO. Learn more about his research, achievements and collaborations with Vial.
Dr. Antoni Ribas is a physician-scientist conducting laboratory and clinical research focused in malignant melanoma. His research includes: laboratory and clinical translational research in adoptive cell transfer therapy with T-cell receptor (TCR) engineered lymphocytes; understanding the antitumor activity of PD-1-blocking antibodies
